Fexinidazole: First Global Approval
Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as ‘sleeping sickness’] and Chagas’ disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against Trypanosoma brucei gambiense and T. b. rhodesiense. Under Article 58 of Regulation (EC) no. 726/2004 (a regulatory mechanism for reviewing new medicines destined for use outside of the EU), fexinidazole has been granted a positive opinion by the EMA for the treatment of both the first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of HAT due to T. b. gambiense (g-HAT) in adults and children aged ≥ 6 years and weighing ≥ 20 kg. This approval will facilitate and support marketing authorization application in endemic countries in 2019; following registration, fexinidazole will be distributed via the WHO to endemic countries for g-HAT. Phase 3 evaluation of fexinidazole for g-HAT is ongoing in the Democratic Republic of the Congo and Guinea and the drug is also in development for Chagas’ disease, with a study currently ongoing in Spain. Clinical development for visceral leishmaniasis is discontinued. This article summarizes the milestones in the development of fexinidazole leading to this first approval for g-HAT.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 3.Drugs for Neglected Diseases Initiative Foundation. Phase II/III studies show high efficacy and safety of fexinidazole, the first oral treatment for sleeping sickness [media release]. http://www.dndi.org. 04 Nov 2017.
- 4.Sanofi. Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment [media release]. 31 Jan 2018.Google Scholar
- 5.European Medicine Agency. Medicines for use outside the European Union. 2018. https://www.ema.europa.eu. Accessed 06 Dec 2018.
- 6.European Medicines Agency. Fexinidazole Winthrop: summary of opinion. https://www.ema.europa.eu/. Accessed 15 Nov 2018.
- 7.Sanofi. European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness [media release]. http://hugin.info/152918/R/2226012/873418.pdf. 17 Nov 2018.
- 8.US National Institutes of Health. ClinicalTrials.gov identifier NCT01980199. 2015. https://clinicaltrials.gov. Accessed 07 Jan 2019.
- 9.Drugs for Neglected Diseases initiative. Donors. 2018. https://www.dndi.org/donate/donors. Accessed 07 Jan 2019.
- 10.Drugs for Neglected Diseases Initiative Foundation. DNDi receives USD 60 million to fill research and development gaps for neglected patients [media release]. http://www.dndi.org. 02 Nov 2014.
- 11.Drugs for Neglected Diseases Initiative Foundation. DNDi receives support from Norwegian Agency for Development Cooperation for its research development on sleeping sickness [media release]. http://www.dndi.org. 22 May 2014.
- 12.World Health Organization. Human African trypanosomiasis. Symptoms, diagnosis and treatment. 2018. https://www.who.int/trypanosomiasis_african/disease/diagnosis/en/. Accessed 07 Jan 2019.
- 24.Signorell A, Torrente M, Scherrer B, et al. Safety and efficacy of fexinidazole against rhodesiense human African trypanosomiasis: approach to conducting a clinical trial for a very rare, neglected disease [abstract no. PS2.088]. Trop Med Int Health. 2015;20(Suppl. 1):337.Google Scholar